{"id":"paclitaxel-ptx","safety":{"commonSideEffects":[{"rate":"60–70","effect":"Peripheral neuropathy"},{"rate":"75–90","effect":"Neutropenia"},{"rate":"40–50","effect":"Anemia"},{"rate":"20–30","effect":"Thrombocytopenia"},{"rate":"50–60","effect":"Myalgia/arthralgia"},{"rate":"80–90","effect":"Alopecia"},{"rate":"40–50","effect":"Nausea/vomiting"},{"rate":"30–40","effect":"Mucositis"},{"rate":"2–5","effect":"Hypersensitivity reaction"}]},"_chembl":{"chemblId":"CHEMBL538342","moleculeType":"Small molecule","molecularWeight":"1345.00"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a microtubule-stabilizing agent that binds to the β-tubulin subunit of microtubules and prevents their disassembly. This stabilization disrupts the dynamic reorganization of the microtubule cytoskeleton required for cell division, trapping cells in mitosis and triggering apoptosis. It is one of the most widely used chemotherapy agents across multiple solid tumor types.","oneSentence":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest in the G2/M phase, leading to cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:25.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Kaposi sarcoma"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":"Unresectable Pancreatic Cancer","enrollment":90},{"nctId":"NCT05411237","phase":"PHASE3","title":"Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2026-09","conditions":"Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma","enrollment":130},{"nctId":"NCT02408822","phase":"NA","title":"Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-09-29","conditions":"Dysfunction of Hemodialysis Vascular Access (Fistula and Graft)","enrollment":52},{"nctId":"NCT05519241","phase":"PHASE1","title":"A Phase I Intravesical PPM Therapy for NMIBC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-10","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":29},{"nctId":"NCT06186700","phase":"PHASE2","title":"Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2023-12-25","conditions":"Breast Cancer Female, Breast Cancer Patients, Neoadjuvant Therapy","enrollment":100},{"nctId":"NCT07050043","phase":"PHASE3","title":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","status":"RECRUITING","sponsor":"Dr Arvindran A/L Alaga","startDate":"2025-05-19","conditions":"NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC","enrollment":123},{"nctId":"NCT06818331","phase":"PHASE2","title":"Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial","status":"RECRUITING","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2025-02-10","conditions":"Glioma","enrollment":20},{"nctId":"NCT04868708","phase":"PHASE2","title":"A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-04-01","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":50},{"nctId":"NCT06793553","phase":"PHASE2","title":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","status":"RECRUITING","sponsor":"Japan Breast Cancer Research Group","startDate":"2024-09-13","conditions":"Metastatic Breast Cancer","enrollment":106},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":"Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV","enrollment":36},{"nctId":"NCT06620029","phase":"PHASE1, PHASE2","title":"BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"BioMimetix JV, LLC","startDate":"2025-04-01","conditions":"Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm","enrollment":27},{"nctId":"NCT06562998","phase":"NA","title":"Pentoxifylline Role Against Chemotherapy-induced Neuropathy","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-07-01","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":72},{"nctId":"NCT02936622","phase":"NA","title":"Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses","status":"COMPLETED","sponsor":"Cook Group Incorporated","startDate":"2017-02-21","conditions":"Peripheral Arterial Disease (PAD)","enrollment":176},{"nctId":"NCT05064618","phase":"PHASE1, PHASE2","title":"Investigator-initiated Clinical Trial of MIKE-1","status":"RECRUITING","sponsor":"Nagoya University","startDate":"2021-08-23","conditions":"Pancreatic Cancer","enrollment":55},{"nctId":"NCT06176339","phase":"PHASE2","title":"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2023-12-15","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT01450722","phase":"PHASE3","title":"Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery","status":"RECRUITING","sponsor":"Kuopio University Hospital","startDate":"2011-10","conditions":"Chronic Lower Limb Ischemia, Peripheral Athero Obstructive Disease, Critical Ischemia","enrollment":400},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT05189535","phase":"PHASE2, PHASE3","title":"\"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients\"","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-10-03","conditions":"Breast Cancer Female, Peripheral Neuropathy","enrollment":66},{"nctId":"NCT05465590","phase":"EARLY_PHASE1","title":"A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer","status":"WITHDRAWN","sponsor":"Mainline Biosciences, Inc.","startDate":"2022-12","conditions":"Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05832827","phase":"PHASE2","title":"First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2023-09-04","conditions":"Untreated Advanced or Recurrent Thymic Carcinomas","enrollment":35},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT02995850","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-02-22","conditions":"Gastric Cancer With Peritoneal Metastasis (PCI<12)","enrollment":25},{"nctId":"NCT05966441","phase":"PHASE2","title":"Role of Curcumin in Paclitaxel Induced PN","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-08-30","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":80},{"nctId":"NCT04850235","phase":"PHASE1","title":"Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-15","conditions":"Nasopharyngeal Cancer","enrollment":36},{"nctId":"NCT02574481","phase":"NA","title":"ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2015-12","conditions":"Atherosclerosis of Native Arteries of the Extremities","enrollment":524},{"nctId":"NCT05833971","phase":"PHASE2","title":"Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-05-01","conditions":"Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT01927068","phase":"NA","title":"STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)","status":"COMPLETED","sponsor":"Spectranetics Corporation","startDate":"2013-07","conditions":"Peripheral Arterial Disease","enrollment":499},{"nctId":"NCT05627414","phase":"PHASE2","title":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT05522894","phase":"PHASE2","title":"AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT05228743","phase":"NA","title":"Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-09-01","conditions":"Gastric Cancer","enrollment":180},{"nctId":"NCT05204173","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-05-20","conditions":"Gastric Cancer Stage IV, Peritoneal Metastases","enrollment":30},{"nctId":"NCT05173857","phase":"NA","title":"Drug Eluting Balloon (DEB) vs Plain Old Balloon Angioplasty (POBA) in the Treatment of Failing Dialysis Access","status":"COMPLETED","sponsor":"Skane University Hospital","startDate":"2014-03-01","conditions":"Vascular Diseases, Kidney Diseases","enrollment":42},{"nctId":"NCT05171530","phase":"PHASE1","title":"Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-01-05","conditions":"HER2-negative Advanced Gastric Cancer","enrollment":19},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT04576143","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-09-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Chemotherapy","enrollment":260},{"nctId":"NCT04781413","phase":"PHASE1, PHASE2","title":"Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-03-01","conditions":"Stage IIIC Gastric Cancer","enrollment":38},{"nctId":"NCT02004951","phase":"NA","title":"BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2014-03-25","conditions":"Peripheral Arterial Disease, Femoropopliteal Lesions","enrollment":186},{"nctId":"NCT01745367","phase":"PHASE2","title":"Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2012-11","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04581265","phase":"PHASE2","title":"Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-11-10","conditions":"Extracranial Germ Cell Tumor, Pediatric","enrollment":43},{"nctId":"NCT02717091","phase":"PHASE2","title":"Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Nagoya University","startDate":"2015-07","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":50},{"nctId":"NCT03078400","phase":"PHASE1","title":"Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer","status":"UNKNOWN","sponsor":"Splash Pharmaceuticals, Inc.","startDate":"2017-03-10","conditions":"Ovarian Epithelial Cancer","enrollment":14},{"nctId":"NCT04204564","phase":"","title":"VISION and VQI Paclitaxel Safety Analysis","status":"UNKNOWN","sponsor":"University of Vermont Medical Center","startDate":"2012-10-01","conditions":"PAD","enrollment":20000},{"nctId":"NCT04153734","phase":"PHASE2","title":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Kobe Minimally Invasive Cancer Center","startDate":"2019-12-01","conditions":"Locally Advanced Non-small Cell Lung Cancer","enrollment":21},{"nctId":"NCT02598310","phase":"PHASE2","title":"Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Osaka Medical College","startDate":"2015-11","conditions":"Breast Cancer, Estrogen Receptor Negative Neoplasm, HER-2 Positive Breast Cancer","enrollment":30},{"nctId":"NCT02254837","phase":"NA","title":"Zilver PTX Post-Market Study in Japan","status":"COMPLETED","sponsor":"Cook Group Incorporated","startDate":"2012-05","conditions":"Peripheral Arterial Disease (PAD)","enrollment":909},{"nctId":"NCT03949634","phase":"PHASE3","title":"Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-09-01","conditions":"Early Breast Cancer","enrollment":272},{"nctId":"NCT03876886","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-02-22","conditions":"Triple Negative Breast Cancer","enrollment":200},{"nctId":"NCT03792074","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-02","conditions":"Non-squamous Cell Non-small Cell Lung Cancer","enrollment":560},{"nctId":"NCT03544047","phase":"NA","title":"Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2019-01-01","conditions":"Organoid","enrollment":50},{"nctId":"NCT03671655","phase":"NA","title":"Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents","status":"TERMINATED","sponsor":"North Texas Veterans Healthcare System","startDate":"2014-01","conditions":"Peripheral Vascular Diseases, Chronic Total Occlusion of Artery of the Extremities","enrollment":4},{"nctId":"NCT02254356","phase":"NA","title":"Zilver Flex Post-Market Study in Japan","status":"COMPLETED","sponsor":"Cook Group Incorporated","startDate":"2012-05","conditions":"Peripheral Arterial Disease (PAD)","enrollment":239},{"nctId":"NCT03045770","phase":"NA","title":"mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2017-02-10","conditions":"Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction","enrollment":150},{"nctId":"NCT02934828","phase":"PHASE2","title":"Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-10","conditions":"Breast Cancer","enrollment":230},{"nctId":"NCT02271529","phase":"NA","title":"Zilver PTX Delivery System","status":"COMPLETED","sponsor":"Cook Group Incorporated","startDate":"2014-09","conditions":"Peripheral Vascular Disease","enrollment":40},{"nctId":"NCT02607982","phase":"PHASE2","title":"CCRT for Esophageal Cancer.","status":"COMPLETED","sponsor":"Hangzhou Cancer Hospital","startDate":"2005-01","conditions":"Esophageal Cancer, Concurrent Chemoradiotherapy, Oxaliplatin","enrollment":34},{"nctId":"NCT01891123","phase":"NA","title":"Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-06","conditions":"Non-small Cell Lung Cancer, Breast Cancer, Nasal Cancer","enrollment":300},{"nctId":"NCT02586753","phase":"PHASE2","title":"Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus","status":"UNKNOWN","sponsor":"Mianyang Central Hospital","startDate":"2015-12","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":2},{"nctId":"NCT00776906","phase":"NA","title":"Advance® 18PTX® Balloon Catheter Study","status":"COMPLETED","sponsor":"Cook Group Incorporated","startDate":"2008-10","conditions":"Peripheral Arterial Disease","enrollment":150},{"nctId":"NCT01728441","phase":"NA","title":"Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery","status":"COMPLETED","sponsor":"Provascular GmbH","startDate":"2012-10","conditions":"Peripheral Artery Disease","enrollment":150},{"nctId":"NCT02033135","phase":"PHASE4","title":"Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2012-06","conditions":"Peripheral Arterial Disease","enrollment":84},{"nctId":"NCT01347424","phase":"PHASE2","title":"Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-01","conditions":"Non Small Cell Lung Cancer, Nasopharyngeal Cancer, Liver Metastasis","enrollment":40},{"nctId":"NCT01378533","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-05","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01298947","phase":"NA","title":"Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions","status":"UNKNOWN","sponsor":"Herz-Zentrums Bad Krozingen","startDate":"2011-04","conditions":"Restenosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD PRESSURE DECREASED"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DRUG HYPERSENSITIVITY"},{"count":1,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":1,"reaction":"PERITONITIS"},{"count":1,"reaction":"RASH"},{"count":1,"reaction":"SKIN DISORDER"},{"count":1,"reaction":"STEVENS-JOHNSON SYNDROME"}],"_approvalHistory":[],"publicationCount":4375,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel (PTX)","genericName":"Paclitaxel (PTX)","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest in the G2/M phase, leading to cancer cell death. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}